Clinical Trials Browser

Phase EARLY_PHASE1 × Nivolumab × 30 days × Clear all

NCT04741997 2026-03-02

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Phase EARLY_PHASE1 Recruiting

Melanoma

NCT07210632 2026-02-27

Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

Phase EARLY_PHASE1 Not yet recruiting

Brain Neoplasms, Glioma